Skip to main content
Access Resources

MJFF Publications

1311 - 1320 of 7540 Results
Title
Year
  • Year
  • 2022
  • 2022
  • 2022
  • 2022
  • 2022
  • 2022
  • 2022
  • 2022
  • 2022
  • 2022
  • RESTRICTED
    Title: ID:16220 Visualization Tool for DBS Programming Used With a Multiple-Source, Constant-Current System Reduces Initial Programming Time
    Journal Name: Neuromodulation: Technology at the Neural Interface
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1016/j.neurom.2022.02.012
    Best OA location URL:
    Citation Count: 0
  • RESTRICTED
    Title: Inconsistency and incongruence: the two diagnostic pillars of functional movement disorder
    Journal Name: The Lancet
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1016/s0140-6736(22)01184-9
    Best OA location URL:
    Citation Count: 5
  • RESTRICTED
    Title: Istradefylline for OFF Episodes in Parkinson’s Disease: A US Perspective of Common Clinical Scenarios
    Journal Name: Degenerative Neurological and Neuromuscular Disease
    Publisher: Informa UK Limited
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License: cc-by-nc
    DOI - Digital Object Identifier: 10.2147/dnnd.s245197
    Citation Count: 1
  • RESTRICTED
    Title: L-Dopa response, choreic dyskinesia, and dystonia in Perry syndrome
    Journal Name: Parkinsonism & Related Disorders
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1016/j.parkreldis.2022.05.023
    Best OA location URL:
    Citation Count: 5
  • RESTRICTED
    Title: Loss of tau expression attenuates neurodegeneration associated with α-synucleinopathy
    Journal Name: Translational Neurodegeneration
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License: cc-by, cc-by
    DOI - Digital Object Identifier: 10.1186/s40035-022-00309-x
    Citation Count: 6
  • RESTRICTED
    Title: LRRK2 as a target for modulating immune system responses
    Journal Name: Neurobiology of Disease
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License: cc-by-nc-nd
    DOI - Digital Object Identifier: 10.1016/j.nbd.2022.105724
    Citation Count: 11
  • RESTRICTED
    Title: Newly Approved and Investigational Drugs for Motor Symptom Control in Parkinson's Disease
    Journal Name: Drugs
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1007/s40265-022-01747-7
    Citation Count: 7
  • RESTRICTED
    Title: Patient Experience in Early-Stage Parkinson’s Disease: Using a Mixed Methods Analysis to Identify Which Concepts Are Cardinal for Clinical Trial Outcome Assessment
    Journal Name: Neurology and Therapy
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License: cc-by-nc
    DOI - Digital Object Identifier: 10.1007/s40120-022-00375-3
    Citation Count: 7
  • RESTRICTED
    Title: Recurrent Biallelic p.L347P PINK1 Variant in Polynesians with Parkinsonism and Isolated Dopa‐Responsive Dystonia
    Journal Name: Movement Disorders Clinical Practice
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License: cc-by
    DOI - Digital Object Identifier: 10.1002/mdc3.13467
    Citation Count: 3
  • RESTRICTED
    Title: Reply to: “Diabetes and Neuroaxonal Damage in Parkinson's Disease”
    Journal Name: Movement Disorders
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1002/mds.29064
    Best OA location URL:
    Citation Count: 0
Filters
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.